|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,875 KRW | +1.25% |
|
-0.91% | -15.36% |
| 2023 | Dong Sung Bio Pharm.Co.,Ltd. announced that it has received KRW 14 billion in funding | CI |
| 2023 | Dong Sung Bio Pharm.Co.,Ltd. announced that it expects to receive KRW 14 billion in funding | CI |
Dong Sung Bio Pharm.Co.,Ltd. (KOSE:A002210) announces a share repurchase program. Under the program, the company will repurchase up to 261,780 shares. The purpose of the program is to improve shareholder value and to stabilize stock price.
The repurchase program will expire on September 23, 2022. As of June 22, 2022, the company had 2,977,992 treasury shares within scope available for dividend and no shares in treasury through other repurchase.
| 1st Jan change | Capi. | |
|---|---|---|
| -15.36% | 79.1M | |
| +20.39% | 43.67B | |
| +28.10% | 22.79B | |
| +21.43% | 15.45B | |
| +18.82% | 14.29B | |
| +53.37% | 12.83B | |
| -0.05% | 6.79B | |
| -12.44% | 6.52B | |
| -8.87% | 5.73B | |
| +15.72% | 5.59B |
DONG SUNG BIO PHARM.CO.,LTD. 
